Dexcom’s leadership said Thursday that the company has fixed problems with its flagship glucose monitor after reports of quality issues with its latest G7 sensor. The diabetes technology company has ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump ...

DexCom Inc. DXCM recently introduced a new direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. With the new feature, G7 is likely to be the first CGM device that can link ...